Epigenetic approaches to overcoming chemotherapy resistance

Por Strauss, Julius, Figg, William D
Publicado no Lancet Oncol (2015)

Using Epigenetic Therapy to Overcome Chemotherapy Resistance

Por STRAUSS, JULIUS, FIGG, WILLIAM D.
Publicado no Anticancer Res (2016)

Evaluating immune responses after sipuleucel-T therapy

Por Strauss, Julius, Madan, Ravi A, Figg, William D
Publicado no Cancer Biol Ther (2015)

Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors

Por Strauss, Julius, Madan, Ravi A., Gulley, James L.
Publicado no Expert Opin Biol Ther (2016)

Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report

Por Cardis, Michael A., Jiang, Hong, Strauss, Julius, Gulley, James L., Brownell, Isaac
Publicado no BMC Cancer (2019)

Anti–PD-L1 Treatment Induced Central Diabetes Insipidus

Por Zhao, Chen, Tella, Sri Harsha, Del Rivero, Jaydira, Kommalapati, Anuhya, Ebenuwa, Ifechukwude, Gulley, James, Strauss, Julius, Brownell, Isaac
Publicado no J Clin Endocrinol Metab (2017)

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances

Por Lind, Hanne, Gameiro, Sofia R, Jochems, Caroline, Donahue, Renee N., Strauss, Julius, Gulley, James L, Palena, Claudia, Schlom, Jeffrey
Publicado no J Immunother Cancer (2020)

Successful 5-fluorouracil (5-FU) infusion re-challenge in a metastatic colorectal cancer patient with coronary artery disease who experienced symptoms consistent with coronary vaso...

Por Redman, Jason M., Rhea, Logan P., Brofferio, Alessandra, Whelpley, Margaret, Gulley, James L., Gatti-Mays, Margaret E., McMahon, Sheri, Cordes, Lisa M., Strauss, Julius
Publicado no J Gastrointest Oncol (2019)

Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis

Por Allen, Clint T., Lee, Sunmin, Norberg, Scott M., Kovalovsky, Damian, Ye, Hong, Clavijo, Paul E., Hu-Lieskovan, Siwen, Schlegel, Richard, Schlom, Jeffrey, Strauss, Julius, Gulley, James L., Trepel, Jane, Hinrichs, Christian S.
Publicado no J Immunother Cancer (2019)

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

Por Bilusic, Marijo, Heery, Christopher R., Collins, Julie M., Donahue, Renee N., Palena, Claudia, Madan, Ravi A., Karzai, Fatima, Marté, Jennifer L., Strauss, Julius, Gatti-Mays, Margaret E., Schlom, Jeffrey, Gulley, James L.
Publicado no J Immunother Cancer (2019)

First-In-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors

Por Strauss, Julius, Heery, Christopher R., Kim, Joseph W., Jochems, Caroline, Donahue, Renee N., Montgomery, Agnes S., McMahon, Sheri, Lamping, Elizabeth, Marté, Jennifer L., Madan, Ravi A., Bilusic, Marijo, Silver, Matthew R., Bertotti, Elisa, Schlom, Jeffrey, Gulley, James L.
Publicado no Clin Cancer Res (2018)

A Phase 1 Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC-1 and CEA with Costimulatory Molecules

Por Gatti-Mays, Margaret E., Strauss, Julius, Donahue, Renee N., Palena, Claudia, Rivero, Jaydira Del, Redman, Jason, Madan, Ravi A., Marté, Jennifer N., Cordes, Lisa, Lamping, Elizabeth, Orpia, Alanvin, Burmeister, Andrea, Wagner, Eva, Navarro, Cesar Pico, Heery, Christopher R., Schlom, Jeffrey, Gulley, James L.
Publicado no Clin Cancer Res (2019)